Other search tools

About this data

The publication data currently available has been vetted by Vanderbilt faculty, staff, administrators and trainees. The data itself is retrieved directly from NCBI's PubMed and is automatically updated on a weekly basis to ensure accuracy and completeness.

If you have any questions or comments, please contact us.

Results: 1 to 10 of 20

Publication Record

Connections

Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma.
Cornell RF, Ky B, Weiss BM, Dahm CN, Gupta DK, Du L, Carver JR, Cohen AD, Engelhardt BG, Garfall AL, Goodman SA, Harrell SL, Kassim AA, Jadhav T, Jagasia M, Moslehi J, O'Quinn R, Savona MR, Slosky D, Smith A, Stadtmauer EA, Vogl DT, Waxman A, Lenihan D
(2019) J Clin Oncol 37: 1946-1955
MeSH Terms: Adult, Aged, Aged, 80 and over, Bortezomib, Cardiovascular Diseases, Disease-Free Survival, Electrocardiography, Female, Heart Diseases, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Molecular Targeted Therapy, Multiple Myeloma, Natriuretic Peptide, Brain, Neoplasm Recurrence, Local, Oligopeptides, Prospective Studies, Proteasome Inhibitors, Risk Factors, Time-to-Treatment, Treatment Outcome, Troponin I, Troponin T
Added November 12, 2019
0 Communities
1 Members
0 Resources
25 MeSH Terms
A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.
Laubach JP, Moslehi JJ, Francis SA, San Miguel JF, Sonneveld P, Orlowski RZ, Moreau P, Rosiñol L, Faber EA, Voorhees P, Mateos MV, Marquez L, Feng H, Desai A, van de Velde H, Elliott J, Shi H, Dow E, Jobanputra N, Esseltine DL, Niculescu L, Anderson KC, Lonial S, Richardson PG
(2017) Br J Haematol 178: 547-560
MeSH Terms: Antineoplastic Agents, Benchmarking, Bortezomib, Cardiovascular Diseases, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Dyspnea, Heart Failure, Humans, Multiple Myeloma, Proteasome Inhibitors, Retrospective Studies, Risk Factors
Added December 2, 2017
0 Communities
1 Members
0 Resources
13 MeSH Terms
Bortezomib augments lymphocyte stimulatory cytokine signaling in the tumor microenvironment to sustain CD8+T cell antitumor function.
Pellom ST, Dudimah DF, Thounaojam MC, Uzhachenko RV, Singhal A, Richmond A, Shanker A
(2017) Oncotarget 8: 8604-8621
MeSH Terms: Adenocarcinoma, Animals, Antineoplastic Agents, Bortezomib, Breast Neoplasms, CD8-Positive T-Lymphocytes, Cell Line, Tumor, Cytokines, Female, Fibrosarcoma, Kidney Neoplasms, Lung Neoplasms, Lymphocytes, Tumor-Infiltrating, Mice, Inbred BALB C, Mice, Transgenic, Phosphatidylinositol 3-Kinase, Proteasome Endopeptidase Complex, Proteasome Inhibitors, Proto-Oncogene Proteins c-akt, Receptors, Cytokine, STAT5 Transcription Factor, Signal Transduction, Tumor Escape, Tumor Microenvironment
Added March 14, 2017
2 Communities
1 Members
0 Resources
24 MeSH Terms
Combined treatment with a transforming growth factor beta inhibitor (1D11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease.
Nyman JS, Merkel AR, Uppuganti S, Nayak B, Rowland B, Makowski AJ, Oyajobi BO, Sterling JA
(2016) Bone 91: 81-91
MeSH Terms: Animals, Bone Diseases, Bone and Bones, Bortezomib, Cancellous Bone, Cell Count, Cell Line, Tumor, Disease Models, Animal, Drug Therapy, Combination, Mice, Inbred C57BL, Multiple Myeloma, Osteoblasts, Receptors, Transforming Growth Factor beta, Signal Transduction, Transforming Growth Factor beta, Tumor Burden
Added July 18, 2016
2 Communities
2 Members
0 Resources
16 MeSH Terms
Neutrophil-Derived IL-1β Impairs the Efficacy of NF-κB Inhibitors against Lung Cancer.
McLoed AG, Sherrill TP, Cheng DS, Han W, Saxon JA, Gleaves LA, Wu P, Polosukhin VV, Karin M, Yull FE, Stathopoulos GT, Georgoulias V, Zaynagetdinov R, Blackwell TS
(2016) Cell Rep 16: 120-132
MeSH Terms: Animals, Bortezomib, Carcinogenesis, Carcinoma, Non-Small-Cell Lung, Cell Proliferation, Epithelial Cells, Humans, I-kappa B Kinase, Interleukin-1beta, Lung Neoplasms, Mice, Myeloid Cells, NF-kappa B, Neutrophils, Signal Transduction, Survival Analysis
Added March 29, 2017
2 Communities
2 Members
0 Resources
16 MeSH Terms
Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression.
Jin R, Yamashita H, Yu X, Wang J, Franco OE, Wang Y, Hayward SW, Matusik RJ
(2015) Oncogene 34: 3700-10
MeSH Terms: Androgen Antagonists, Anilides, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Boronic Acids, Bortezomib, Cell Line, Tumor, Humans, Male, NF-kappa B, Nitriles, Prostatic Neoplasms, Castration-Resistant, Pyrazines, Receptors, Androgen, Signal Transduction, Tosyl Compounds, Xenograft Model Antitumor Assays
Added January 20, 2015
1 Communities
3 Members
0 Resources
17 MeSH Terms
Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group.
Ciombor KK, Feng Y, Benson AB, Su Y, Horton L, Short SP, Kauh JS, Staley C, Mulcahy M, Powell M, Amiri KI, Richmond A, Berlin J
(2014) Invest New Drugs 32: 1017-27
MeSH Terms: Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Boronic Acids, Bortezomib, Carcinoma, Hepatocellular, Chemokine CCL5, Cytokines, Disease-Free Survival, Doxorubicin, Female, Humans, Liver Neoplasms, Male, Middle Aged, Pyrazines, Treatment Outcome, Vascular Endothelial Growth Factor A, Young Adult
Added August 7, 2014
2 Communities
2 Members
0 Resources
19 MeSH Terms
Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo.
Escalante AM, McGrath RT, Karolak MR, Dorr RT, Lynch RM, Landowski TH
(2013) Cancer Chemother Pharmacol 71: 1567-76
MeSH Terms: Animals, Antineoplastic Agents, Apoptosis, Autophagy, Boronic Acids, Bortezomib, Calpain, Cell Line, Tumor, Cell Survival, Drug Synergism, HIV Protease Inhibitors, Humans, Mice, Mice, SCID, Multiple Myeloma, Nelfinavir, Pyrazines, RNA, Small Interfering, Xenograft Model Antitumor Assays
Added August 19, 2013
0 Communities
1 Members
0 Resources
19 MeSH Terms
Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): a trial of the Eastern Cooperative Oncology Group.
Gilbert J, Lee JW, Argiris A, Haigentz M, Feldman LE, Jang M, Arun P, Van Waes C, Forastiere AA
(2013) Head Neck 35: 942-8
MeSH Terms: Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Boronic Acids, Bortezomib, Camptothecin, Carcinoma, Squamous Cell, Cytokines, Disease Progression, Female, Head and Neck Neoplasms, Humans, Irinotecan, Male, Middle Aged, NF-kappa B, Pyrazines, Squamous Cell Carcinoma of Head and Neck, Treatment Outcome
Added March 5, 2014
0 Communities
1 Members
0 Resources
20 MeSH Terms
Opposing effects of bortezomib-induced nuclear factor-κB inhibition on chemical lung carcinogenesis.
Karabela SP, Psallidas I, Sherrill TP, Kairi CA, Zaynagetdinov R, Cheng DS, Vassiliou S, McMahon F, Gleaves LA, Han W, Stathopoulos I, Zakynthinos SG, Yull FE, Roussos C, Kalomenidis I, Blackwell TS, Stathopoulos GT
(2012) Carcinogenesis 33: 859-67
MeSH Terms: Animals, Antineoplastic Agents, Boronic Acids, Bortezomib, Cell Line, Cell Line, Tumor, Humans, Lung Neoplasms, Mice, Mice, Inbred BALB C, NF-kappa B, Pyrazines
Added February 26, 2013
1 Communities
1 Members
0 Resources
12 MeSH Terms